Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $86.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 8.86% year-over-year to $86.2 million; the TTM figure through Mar 2026 stood at $86.2 million (down 8.86% YoY), while the FY2025 annual figure was $120.1 million, up 16.0% from the prior year.
• Total Current Liabilities was $86.2 million for Q1 2026 at Syndax Pharmaceuticals, down from $120.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $120.1 million in Q4 2025 to a low of $20.8 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $61.6 million across 5 years, with a median of $50.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities decreased 27.55% in 2022, then jumped 166.03% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $29.1 million in 2022, then surged by 99.88% to $58.1 million in 2023, then surged by 78.24% to $103.5 million in 2024, then climbed by 16.0% to $120.1 million in 2025, then retreated by 28.26% to $86.2 million in 2026.
• The last three Total Current Liabilities figures came in at $86.2 million (Q1 2026), $120.1 million (Q4 2025), and $114.2 million (Q3 2025), per Business Quant data.